Novartis
Senators call on FDA to use “forceful response” against Novartis over faulty data scandal
August 12, 2019Sales and Marketing AveXis, Bernie Sanders, Elizabeth Warren, FDA, Novartis, Zolgensma
Five senators, including presidential candidates Bernie Sanders and Elizabeth Warren, have condemned Novartis for using “falsified data… to obtain approval …
Top Ten most popular articles on Pharmafile.com this week!
August 9, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, CAR T, CAR-T, Eli Lilly, Lexicon, Medicare, Novartis, Pfizer, Sanofi, pharma
This week’s top story covered the scandal surrounding Novartis over its covering up of faulty data from the FDA. The …
Medicare will cover CAR-T therapies in United States
August 8, 2019Sales and Marketing CAR-T therapies, Cancer, Gilead, Kymriah, Medicare, Novartis, keytruda, pharma
Medicare will cover the cost of Novartis’ and Gilead’s CAR-T therapies Kymriah and Yescarta, the US Centers for Medicare and …
Novartis hid faulty data from FDA over $2.1 million gene therapy Zolgensma
August 7, 2019Research and Development AveXis, FDA, Novartis, Zolgensma, gene therapy, pharma
Novartis hid faulty data from the FDA until their drug was approved, according to a statement from Dr Peter Marks, …
Novartis’ Kisqali reinforces overall survival benefit in postmenopausal HR+/HER2- breast cancer
August 1, 2019Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma
New Phase 3 evidence has emerged on the efficacy of Novartis’ Kisqali (ribociclib) in combination with AstraZeneca’s Faslodex (fulvestrant) in …
Novartis’ Entresto falls short at Phase 3 in heart failure with preserved ejection fraction
July 29, 2019Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma
Novartis has been rocked by new Phase 3 data from a global trial into the efficacy of Entresto (sacubitril/valsartan), revealing …
Gilead buys Novartis’ herpes, flu and cold virus preclinical programmes
July 23, 2019Manufacturing and Production Gilead, Novartis, antivrial, deal, herpes, influenza, rhinovirus
Gilead has acquired the rights to three of Novartis’ preclinical antiviral programmes, including investigational compounds with the potential to treat …
Top Ten most popular articles on Pharmafile.com this week!
July 19, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AMAL Therapeutics, Alzheimer's Ebola, Amgen, AstraZeneca, EMA, FDA, Novartis, pharma
On 12 July news broke that Novartis, Amgen and Banner’s Alzheimer’s Institute were discontinuing a trial into investigational compound CNP520 …
A decade after US approval, Novartis’ Gilenya scores marketing authorisation in China for relapsing multiple sclerosis
July 19, 2019Medical Communications, Sales and Marketing Novartis, gilenya, multiple sclerosis, pharma
Novartis has revealed that its disease modifying drug Gilenya (fingolimod) has secured approval in China for the treatment of relapsing …
Novartis CEO sets aside $700 million to settle bribery lawsuit
July 18, 2019Business Services, Sales and Marketing Novartis, bribery, lawsuit, pharma, sales
Vas Narasimhan, Novartis’ CEO, has set aside $700 million to settle a bribery lawsuit in the United States. Speaking in …
NICE greenlights Novartis Kisqali combo in HR+/HER2- advanced breast cancer
July 17, 2019Manufacturing and Production, Medical Communications, Research and Development Cancer, Kisqali, NICE, Novartis, UK, breast cancer, pharma
Novartis’ Kisqali (ribociclib) has secured recommendation from NICE in combination with fulvestrant, meaning the cyclin-dependent kinase 4 and 6 (CDK4/6) …
Top Ten most popular articles on Pharmafile.com this week!
July 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, HPV, NHS, NICE, Novartis, Pfizer, Trump, pharma, vaccines
This week’s most popular story covered news of Trump’s claims that he will introduce an executive order to ensure the …
Novartis and Amgen halt trials into Alzheimer’s drug after patients get worse
July 12, 2019Medical Communications Alzheimer's, Amgen, Banner Alzheimer's Institute, Novartis, dementia, pharma, research
Novartis, Amgen and Banner Alzheimer’s Institute have dropped a study into investigational Alzheimer’s drug CNP520 (umibecestat) after some patient’s conditions …
Novartis aims to solve EpiPen shortage with generic launch of Symjepi to US pharmacies
July 10, 2019Manufacturing and Production, Research and Development, Sales and Marketing Mylan, Novartis, Sandoz, US, epipen, pharma
Novartis has announced the immediate availability of its generic epinephrine auto-injector in pharmacies throughout the US, as it moves to …
Top Ten most popular articles on Pharmafile.com this week!
July 5, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brenntag, Elizabeth Warren, HIV, Novartis, PrEP, cannabis, crispr, pharma
The top story of this week covered Novartis’ announcement that they did not send chemicals that could be used to …
